Protein kinase C inhibitor Gö6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model

Gynecologic Oncology

Volumn 110, Issue 3, 2008, Pages 425-431

  Qamar, Lubna ^a   Davis, Ryan ^a   Anwar, Adil ^b   Behbakht, Kian ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

A2780 cell line; Caffeine; CDDP; G 6976; Ovarian cancer; SKOV3 cell line

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; CAFFEINE; CISPLATIN; PROTEIN KINASE B; PROTEIN KINASE C INHIBITOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL STRAIN A2780; CELL STRAIN SKOV3; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CAFFEINE; CARBAZOLES; CELL CYCLE; CELL DIVISION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; G2 PHASE; HUMANS; OVARIAN NEOPLASMS; PROTEIN KINASE C;

EID: 50149111526     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.04.039     Document Type: Article

References (33)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 55 1 (2005) 10-30
2. Guppy A.E., Nathan P.D., and Rustin G.J. Epithelial ovarian cancer: a review of current management. Clin Oncol (R Coll Radiol) 17 6 (2005) 399-411
3. Ozols R.F. Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol 33 2 Suppl 6 (2006) S3-11
4. Lau C.C., and Pardee A.B. Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc Natl Acad Sci U S A 79 9 (1982) 2942-2946
5. Yao S.L., Akhtar A.J., McKenna K.A., Bedi G.C., Sidransky D., Mabry M., et al. Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase. Nat Med 2 10 (1996) 1140-1143
6. Husain A., Rosales N., Schwartz G.K., and Spriggs D.R. Lisofylline sensitizes p53 mutant human ovarian carcinoma cells to the cytotoxic effects of cis-diamminedichloroplatinum (II). Gynecol Oncol 70 1 (1998) 17-22
7. Tsuchiya H., Mori Y., Ueda Y., Okada G., and Tomita K. Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma. Anticancer Res 20 1A (2000) 235-242
8. Husain A., Yan X.J., Rosales N., Aghajanian C., Schwartz G.K., and Spriggs D.R. UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II)independent of p53 status. Clin Cancer Res 3 11 (1997) 2089-2097
9. Boike G.M., Petru E., Sevin B.U., Averette H.E., Chou T.C., Penalver M., et al. Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line. Gynecol Oncol 38 3 (1990) 315-322
10. Kaplan G.B., Greenblatt D.J., Ehrenberg B.L., Goddard J.E., Cotreau M.M., Harmatz J.S., et al. Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol 37 8 (1997) 693-703
11. Bunch R.T., and Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res 2 5 (1996) 791-797
12. Lee S.I., Brown M.K., and Eastman A. Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines. Biochem Pharmacol 58 11 (1999) 1713-1721
13. Seynaeve C.M., Stetler-Stevenson M., Sebers S., Kaur G., Sausville E.A., and Worland P.J. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res 53 9 (1993) 2081-2086
14. Fuse E., Kuwabara T., Sparreboom A., Sausville E.A., and Figg W.D. Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J Clin Pharmacol 45 4 (2005) 394-403
15. Sausville E.A. Cell cycle regulatory kinase modulators: interim progress and issues. Curr Top Med Chem 5 12 (2005) 1109-1117
16. Jiang X., Lim L.Y., Daly J.W., Li A.H., Jacobson K.A., and Roberge M. Structure-activity relationships for G2 checkpoint inhibition by caffeine analogs. Int J Oncol 16 5 (2000) 971-978
17. Kohn E.A., Yoo C.J., and Eastman A. The protein kinase C inhibitor Go6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res 63 1 (2003) 31-35
18. Ramos-Lima F.J., Quiroga A.G., Garcia-Serrelde B., Blanco F., Carnero A., and Navarro-Ranninger C. New trans-platinum drugs with phosphines and amines as carrier ligands induce apoptosis in tumor cells resistant to cisplatin. J Med Chem 50 9 (2007) 2194-2199
19. Behbakht K., Qamar L., Aldridge C.S., Coletta R.D., Davidson S.A., Thorburn A., et al. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res 67 7 (2007) 3036-3042
20. Kruk P.A., Maines-Bandiera S.L., and Auersperg N. A simplified method to culture human ovarian surface epithelium. Lab Invest 63 1 (1990) 132-136
21. Auersperg N., Siemens C.H., and Myrdal S.E. Human ovarian surface epithelium in primary culture. In Vitro 20 10 (1984) 743-755
22. Gregoire L., Munkarah A., Rabah R., Morris R.T., and Lancaster W.D. Organotypic culture of human ovarian surface epithelial cells: a potential model for ovarian carcinogenesis. In Vitro Cell Dev Biol Anim 34 8 (1998) 636-639
23. Medzihradsky F., and Marks M.J. Measures of viability in isolated cells. Biochem Med 13 2 (1975) 164-177
24. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 66 1 (1975) 188-193
25. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 5259 (1970) 680-685
26. Towbin H., Staehelin T., and Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 76 9 (1979) 4350-4354
27. Deplanque G., Ceraline J., Mah-Becherel M.C., Cazenave J.P., Bergerat J.P., and Klein-Soyer C. Caffeine and the G2/M block override: a concept resulting from a misleading cell kinetic delay, independent of functional p53. Int J Cancer 94 3 (2001) 363-369
28. Barratt R.A., Kao G., McKenna W.G., Kuang J., and Muschel R.J. The G2 block induced by DNA damage: a caffeine-resistant component independent of Cdc25C, MPM-2 phosphorylation, and H1 kinase activity. Cancer Res 58 12 (1998) 2639-2645
29. Deplanque G., Ceraline J., Lapouge G., Dufour P., Bergerat J.P., and Klein-Soyer C. Conflicting effects of caffeine on apoptosis and clonogenic survival of human K1 thyroid carcinoma cell lines with different p53 status after exposure to cisplatin or UVc irradiation. Biochem Biophys Res Commun 314 4 (2004) 1100-1106
30. Luo J., Manning B.D., and Cantley L.C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4 4 (2003) 257-262
31. Mills G.B., Kohn E., Lu Y., Eder A., Fang X., Wang H., et al. Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol 30 5 Suppl 16 (2003) 93-104
32. Osaki M., Kase S., Adachi K., Takeda A., Hashimoto K., and Ito H. Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45. J Cancer Res Clin Oncol 130 1 (2004) 8-14
33. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10 2 (1998) 262-267